QR Code

Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 196-Week Results from the KEEPsAKE 1 and KEEPsAKE 2 Randomized Clinical Trials

Abstract Introduction The ongoing KEEPsAKE 1 and 2 (KS1; KS2) trials evaluate the efficacy and safety of risankizumab in patients with psoriatic arthritis (PsA) who had an inadequate response to ≥ 1 conventional synthetic disease-modifying antirheumatic drug(s) (csDMARD-IR, KS1&2) and/or 1–2 biologi...

Full description

Saved in:
Main Authors: Andrew Östör, Filip Van den Bosch, Kim Papp, Mauro Keiserman, Ricardo Blanco, Angela Crowley, Douglas White, Ana Biljan, Tshepiso Madihlaba, Kyle Carter, Fang Liu, Ahmed M. Soliman, Doug Ashley, Michael Chen, Lila Glotfelty, Alan Kivitz
Format: Artigo
Language:Inglês
Published: Adis, Springer Healthcare 2025-09-01
Series:Rheumatology and Therapy
Subjects:
bDMARD-IR
csDMARD-IR
IL-23
KEEPsAKE 1
KEEPsAKE 2
Long-term treatment
Online Access:https://doi.org/10.1007/s40744-025-00793-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items